NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood?
Harvard Medical School, Boston, MA, USA. sarah.deferranti@cardio.chboston.org
Sarah D
SD
de Ferranti
Stephen R
SR
Daniels
Matthew
M
Gillman
Louis
L
Vernacchio
Jorge
J
Plutzky
Annette L
AL
Baker
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002648:Child; D002784:Cholesterol / Q000097:blood*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D008403:Mass Screening / Q000191:economics / Q000941:ethics; D054555:National Heart, Lung, and Blood Institute (U.S.); D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D012306:Risk; D014481:United States
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol